NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NAMS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.21B
- EPS (TTM)
- -$1.69
- Dividend yield
- None
- 52-week range
- 17.90 – 42.21
- Day range
- 18.29 – 19.78
- Volume / Avg
- 1.74M / 1.66M
- Beta
- —
- Shares outstanding
- 119.93M
52-week range
NAMS stock today
NewAmsterdam Pharma N.V. (NAMS) closed at $18.41 on Nov 20, down 5.64% (-$1.10), versus the S&P 500's 3.70% decline. Shares are 56.4% below their 52-week high of $42.21, set on May 11, 2026 and 2.8% above the 52-week low of $17.90, near the bottom of the past year's range. NAMS is down 47.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 51.9%.
NewAmsterdam Pharma N.V. has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NewAmsterdam Pharma N.V.
Company profileNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Headquarters
- Naarden
- Employees
- 100
- Website
- newamsterdampharma.com
Financial highlights
Full financialsIn fiscal 2025, NewAmsterdam Pharma N.V. generated $22.5 million in revenue, down 50.6% from fiscal 2024, its first annual decline since 2023. NewAmsterdam Pharma N.V. reported a net loss of $203.8 million, compared with a loss of $241.6 million a year earlier. Operating margin was -1002.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $22.50M | $45.56M | $14.09M | $102.69M | — |
| Growth | -50.61% | +223.37% | -86.28% | — | — |
| Net income | $-203.82M | $-241.60M | $-176.94M | $-22.63M | $-41.78M |
| EPS (diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$50.60+174.85%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.14 vs $-0.50
- Surprise
- +72.00%
NAMS news
All NAMS news- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma Company N.V. Reports Third Quarter Financial Results and European Commission ApprovalNasdaq
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsGlobeNewswire
NewAmsterdam Pharma N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs NAMS |
| PHVSPharvaris N.V. | 31.28 | -1.20% | $2.21B | vs NAMS |
| LKFTLakefront Biotherapeutics ADR | 33.31 | -0.24% | $2.18B | vs NAMS |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs NAMS |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs NAMS |
| PVLAPalvella Therapeutics Inc. | 142.85 | -2.00% | $2.09B | vs NAMS |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs NAMS |
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs NAMS |
Indexes, lists and sector
NewAmsterdam Pharma N.V. stock FAQ
What is NewAmsterdam Pharma N.V.'s stock price today?
NAMS last traded at $18.41 as of Nov 20, 4:00 PM EST, down 5.64% on the day. Prices are delayed at least 15 minutes.
Who is NewAmsterdam Pharma N.V.'s CEO?
Dr. Michael Harvey Davidson FACC, Facp., M.D. is the chief executive officer of NewAmsterdam Pharma Company N.V., which has about 100 employees.
What is the NAMS 52-week high?
The 52-week high for NAMS is $42.21 and the 52-week low is $17.90. The stock is currently 56.4% below its high.